Cancel
Kristina Masson
Co-Founder, EVP, Business Operations, Site Head, Director
@
Acrivon Therapeutics
zl8y8t8@hj4bjhx.e08
Sign up to see email
See Linkedin
Known information
- Expertise in cancer biology, predictive biomarkers, and novel therapeutics development
- Founder, President, and CEO of OncoSignature (acquired by Acrivon)
- Established and leads Acrivon's phosphoproteomic hub and early drug programs based on the company's proprietary AP3 platform
- Previously cross-functional team lead at Merrimack Pharmaceuticals
- Completed a Post-Doctoral Fellowship at the Broad Institute of MIT and Harvard
- Developed assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer
- Received an Executive MBA from the Massachusetts Institute of Technology Sloan School of Management
- Received a M.Sc. and Ph.D. from Lund University, Sweden
- Member of the Board of Directors for Aqilion AB
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information